Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04358770 · ClinicalTrials.gov registry record · Phase 1

Bio-equivalence Vasoconstriction Activity Study for Topically Applied Clocortolone Pivalate 0.1% Cream

A Phase 1 study, sponsored by Sun Pharmaceutical Industries.

Completed
Registry status
Phase 1
Development phase
124
Enrollment target

NCT04358770: Completed Phase 1 study, sponsored by Sun Pharmaceutical Industries.

NCT04358770 is a Phase 1 study that has completed, run by Sun Pharmaceutical Industries. The registered enrollment target is 124 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (107% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04358770, a Phase 1 study, has completed, sponsored by Sun Pharmaceutical Industries.

COMPLETED
Registry status
Phase 1
Development phase
124 participants
Enrollment target

Study Summary

To compare pharmacodynamic vasoconstriction response profile of Clocortolone Pivalate 0.1% Cream and Cloderm® (Clocortolone Pivalate) 0.1% Cream in normal skin of healthy male and female adults

Primary Outcome

value for the blanching intensity vs. time profile

Interventions

  • DRUG Clocortolone Pivalate

Trial Details

FieldValue
Enrollment Target 124 participants
Start Date 2018-03-02
Est. Completion 2018-05-11
Phase Phase 1
Sun Pharmaceutical Industries

48 total trials

What the finished NCT04358770 record still lists

NCT04358770 is an interventional study that assigns participants to a tested intervention. The registered 124 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (107% higher).

The record links to 0 conditions, and to 1 intervention - of which Clocortolone Pivalate is the first listed.

NCT04358770 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04358770 about?

NCT04358770 is a clinical study titled "Bio-equivalence Vasoconstriction Activity Study for Topically Applied Clocortolone Pivalate 0.1% Cream". To compare pharmacodynamic vasoconstriction response profile of Clocortolone Pivalate 0.1% Cream and Cloderm® (Clocortolone Pivalate) 0.1% Cream in normal skin of healthy male and female adults

What is the current status of trial NCT04358770?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 124 participants. The study started on 2018-03-02. Estimated completion is 2018-05-11.

What interventions are being tested in trial NCT04358770?

The interventions under investigation include: Clocortolone Pivalate (DRUG).

Who is sponsoring clinical trial NCT04358770?

This trial is sponsored by Sun Pharmaceutical Industries, which has 48 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04358770's enrollment target sits among peer trials

124 471st of 2000 higher than 1,526 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02523014 · 124 participants · Phase 2

    Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

  • NCT02670707 · 124 participants · Phase 3

    Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)

  • NCT02830724 · 124 participants · Phase 1

    Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers

  • NCT04748809 · 124 participants · NA

    Effect of Anti-inflammatory Diet in Rheumatoid Arthritis

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04358770, the US trial registry maintained by the National Library of Medicine. NCT04358770 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.